Heron Therapeutics (HRTX) Osake Kurssi

Heron Therapeutics Inc is primarily active in the pharmaceutical industry.

The main competitors of Heron Therapeutics Inc in the market include companies like Pfizer Inc., Johnson & Johnson, and AbbVie Inc.

Heron Therapeutics Inc is a pharmaceutical company focused on developing innovative treatments for patients suffering from pain and other unmet medical needs. Established in 1983, Heron Therapeutics has grown steadily over the years, establishing itself as a leader in the field of therapeutics. With a dedication to research and development, the company has successfully brought several products to market, aiming to improve the lives of patients worldwide. Heron Therapeutics Inc's commitment to scientific advancements and patient-centered solutions has garnered recognition and resulted in partnerships with prominent healthcare organizations. With a rich history of innovation, Heron Therapeutics Inc continues to strive towards improving healthcare options and making a positive impact on people's lives.

Heron Therapeutics Inc has achieved several significant milestones. Notably, the company received approval from the U.S. Food and Drug Administration (FDA) for SUSTOL®, their extended-release injection for the prevention of chemotherapy-induced nausea and vomiting. Additionally, Heron Therapeutics developed CINVANTI®, a solution for intravenous use in the same indication. The company has also made advancements in their pain management portfolio, introducing HTX-011, a long-acting local anesthetic, which received FDA approval for postoperative pain management. Heron Therapeutics continues to pursue innovation and deliver effective solutions in the pharmaceutical industry.

Heron Therapeutics Inc is primarily present in the United States.

Heron Therapeutics Inc represents values of innovation, commitment to patient well-being, and scientific excellence. The company's corporate philosophy revolves around developing novel, patient-centered therapeutic solutions to address unmet medical needs. Heron Therapeutics Inc prioritizes the discovery and development of innovative medicines to improve the lives of patients, focusing on areas such as pain management and supportive care. With a strong emphasis on scientific rigor and collaboration, the company constantly strives to deliver cutting-edge healthcare solutions, making a positive impact on patients' lives.

7 analyytikkoa arvioi tällä hetkellä Heron Therapeutics-osaketta: 0 suosittaa ostoa, 4 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat Heron Therapeutics-yhtiöltä 148,25 M USD liikevaihtoa ja −0,13 USD osakekohtaista tulosta.

Heron Therapeutics Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Heron Therapeutics-osake noteerataan hintaan 0,34 EUR (0,38 USD).

Heron Therapeutics-osake (HRTX) on listattuna 7 pörssissä, muun muassa: NASDAQ (HRTX), London (0J4V.L), SIX (Zürich) (AXD2.SW), Frankfurt (AXD2.F), München (AXD2.MU), Düsseldorf (AXD2.DU).

Heron Therapeutics Inc is a biopharmaceutical company specializing in the development and commercialization of products for pain treatment and the relief of nausea and vomiting in cancer patients. The company has been operating in the biotech industry since 1983 and is headquartered in San Diego, California. Heron Therapeutics' business model consists of various areas, with the main ones being research and development, production and supply chain, and marketing and sales. The research and development department of Heron Therapeutics develops innovative therapy approaches for pain treatment and relief of nausea and vomiting. This involves the development of both novel active substances and innovative combinations of active substances to ensure optimal treatment of pain and symptoms. Heron Therapeutics produces its products in-house and maintains a high quality standard. Production is an important part of Heron Therapeutics' business model. The continuous monitoring of processes and compliance with safety standards and quality regulations are of primary importance. In-house production enables rapid market launch and quick adaptation to changing market conditions. Heron Therapeutics has an extensive distribution network and serves customers worldwide. The company's distribution strategy is based on targeted customer segmentation, high sales competence, and optimal market penetration. Heron Therapeutics works closely with partners to establish a comprehensive network and effectively market products in target markets. One important product of Heron Therapeutics is ZYNRELEF, a long-acting local anesthetic for the treatment of postoperative pain. The medication is injected subcutaneously and provides long-lasting pain relief. Another important product is CINVANTI, an intravenously administered medication for the prevention of chemotherapy-induced nausea and vomiting. CINVANTI is based on an established active substance but works faster and more effectively than other products on the market. Overall, Heron Therapeutics' business model is characterized by a clear focus on innovation and customer needs. The company utilizes modern research approaches to develop novel therapies and places great importance on safety and efficacy. Heron Therapeutics has a wide portfolio of products for pain treatment and relief of nausea and vomiting in cancer therapy and has established a worldwide distribution network to provide optimal treatment for patients.

odotettu liikevaihto Heron Therapeutics on 148,25 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Heron Therapeutics on −21,67 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Heron Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −2,94. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Heron Therapeutics-osakkeen arvostusta.

Heron Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,43. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Heron Therapeutics-osakkeen arvostuskennuslukuna.

Heron Therapeutics:n Eulpool-laatuscore on 4/10.

Heron Therapeutics:n ISIN on US4277461020. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Heron Therapeutics:n WKN on A1XB6K. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Heron Therapeutics:n ticker on HRTX. Tämä pörssinoteeraus käytetään Heron Therapeutics-osakkeiden kauppaan pörssissä.